WEC
LCTX icon

Winslow Evans & Crocker’s Lineage Cell Therapeutics LCTX Stock Holding History

Winslow Evans & Crocker’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,029
Closed -$2.83K – 1199
2017
Q2 		$2.83K Buy
+1,029
New +$2.88K ﹤0.01% 1142
2014
Q3 		– Sell
-13,629
Closed -$33.5K – 1413
2014
Q2 		$33.5K Buy
13,629
+6,195
+83% +$14K 0.01% 569
2014
Q1 		$19.7K Hold
7,434
– – 0.01% 678
2013
Q4 		$22K Buy
+7,434
New +$22.5K 0.01% 671

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Winslow Evans & Crocker's LCTX Position: Q3 2017 in Review

Winslow Evans & Crocker sold out of Lineage Cell Therapeutics (LCTX) in Q3 2017, closing a stake of 1,029 shares — an estimated $2.83K sold.

Winslow Evans & Crocker first reported a position in LCTX in Q4 2013 and held it in 4 quarters. The position peaked at $33.5K in Q2 2014. 102 funds tracked by Wall St. Rank hold LCTX as of Q3 2017.

  • Winslow Evans & Crocker reported no remaining Lineage Cell Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Winslow Evans & Crocker sold 1,029 Lineage Cell Therapeutics shares in Q3 2017, an estimated $2.83K.
  • Winslow Evans & Crocker first reported a position in Lineage Cell Therapeutics in Q4 2013 and held it in 4 quarters.
  • Winslow Evans & Crocker's Lineage Cell Therapeutics position peaked at $33.5K in Q2 2014.
  • 102 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2017.

Based on Winslow Evans & Crocker's 13F filing for Q3 2017, filed 19 Oct 2017.